Quick Heal Tech

Why is Quick Heal Technologies Ltd falling/rising?

As of 02-Sep, Quick Heal Technologies Ltd's stock price is rising to 137.85, reflecting a short-term positive trend despite significant year-to-date and annual declines of 48.19% and 54.13%, respectively. Recent gains are noted, but declining investor participation indicates potential caution.

As of 02-Sep, Quick Heal Technologies Ltd's stock price is rising, currently at 137.85, with a change of 0.4 (0.29%) upward. This increase can be attributed to the stock outperforming its sector by 2.16% today and experiencing consecutive gains over the last two days, resulting in a total return of 1.5% during this period. Additionally, the current price is higher than the 5-day moving average, indicating a short-term positive trend. However, it is important to note that the stock has been underperforming over longer periods, with significant declines of 48.19% year-to-date and 54.13% over the past year. Despite this, the recent performance suggests a temporary upward movement, although investor participation has been declining, as evidenced by a 19.75% drop in delivery volume compared to the 5-day average.

Which are the latest news on Quick Heal Tech?

Who are in the management team of Quick Heal Tech?

The management team of Quick Heal Tech includes Kailash Sahebrao Katkar (Managing Director & CEO), Sanjay Sahebrao Katkar (Joint Managing Director & CTO), and several independent directors, along with a Company Secretary. They are responsible for guiding the company's strategy and operations.

The management team of Quick Heal Tech includes the following key members:<BR><BR>1. **Kailash Sahebrao Katkar** - Managing Director & CEO<BR>2. **Sanjay Sahebrao Katkar** - Joint Managing Director & CTO<BR>3. **Shailesh Lakhani** - Director<BR>4. **Apurva Pradeep Joshi** - Independent Director<BR>5. **Amitabha Mukhopadhyay** - Independent Director<BR>6. **Bhushan Gokhale** - Independent Director<BR>7. **Srinivasa Rao Anasingaraju** - Company Secretary & Compliance Officer<BR>8. **Richard Stiennon** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategy and operations.

What does Quick Heal Tech do?

Quick Heal Technologies Ltd is a micro-cap company specializing in cybersecurity solutions, with recent quarterly net sales of 45 Cr and a net loss of 5 Cr. Founded in 1995, it has a market cap of INR 767 Cr and operates from Pune, Maharashtra.

Overview:<BR>Quick Heal Technologies Ltd is a micro-cap company operating in the software products industry, specializing in cybersecurity solutions.<BR><BR>History:<BR>The company was incorporated in 1995 as CAT Computer Services Private Limited and later changed its name to Quick Heal Technologies Private Limited in 2007. The most recent quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 45 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: -5 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap: INR 767 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 22<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.50<BR>- Return on Equity: -2.50%<BR>- Price to Book: 1.73<BR><BR>Contact Details:<BR>- Address: Marvel Edge 7th Floor, Office No 7010 C&D Viman Nagar Pune Maharashtra : 411014<BR>- Tel: 91-20-66813232<BR>- Email: cs@quickheal.com<BR>- Website: http://www.quickheal.com

Who are the peers of the Quick Heal Tech?

Quick Heal Tech's peers include Ramco Systems, Nucleus Soft, Blue Cloud Soft, Subex, Unicommerce, IRIS Regtech Sol, and ABM Knowledge. Quick Heal Tech has below-average growth and the lowest 1-year return at -52.52% among its peers.

Peers: The peers of Quick Heal Tech are Ramco Systems, Nucleus Soft., Blue Cloud Soft., Subex, Unicommerce, IRIS Regtech Sol, and ABM Knowledge.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nucleus Soft. and Unicommerce, while Average management risk is found at Ramco Systems, Blue Cloud Soft., Subex, Quick Heal Tech, IRIS Regtech Sol, ABM Knowledge, and the rest. Below Average management risk is noted at Ramco Systems, while Good growth is seen at Nucleus Soft. and Unicommerce, with Average growth at Blue Cloud Soft. and Subex, and Below Average growth at Quick Heal Tech, IRIS Regtech Sol, ABM Knowledge, and the rest. Excellent capital structure is present at Nucleus Soft. and Unicommerce, while Good capital structure is found at Quick Heal Tech and Subex, and Below Average capital structure is noted at Ramco Systems, Blue Cloud Soft., IRIS Regtech Sol, ABM Knowledge, and the rest.<BR><BR>Return Snapshot: Subex has the highest 1-year return at 47.53%, while Quick Heal Tech has the lowest at -52.52%. Quick Heal Tech's 1-year return is significantly lower than all its peers. Additionally, the six-month return is negative for Quick Heal Tech, Blue Cloud Soft., Nucleus Soft., and ABM Knowledge.

How big is Quick Heal Tech?

As of 31st August, Quick Heal Technologies Ltd has a market capitalization of 767.00 Cr and reported net sales of 248.78 Cr with a net loss of 10.70 Cr over the latest four quarters. Shareholder's funds are valued at 436.52 Cr, and total assets amount to 529.47 Cr as of March 2026.

As of 31st August, Quick Heal Technologies Ltd has a market capitalization of 767.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Quick Heal Technologies Ltd reported net sales of 248.78 Cr. However, the company experienced a net loss of 10.70 Cr during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's funds are valued at 436.52 Cr, while total assets amount to 529.47 Cr.

Should I buy, sell or hold Quick Heal Technologies Ltd?

Are Quick Heal Technologies Ltd latest results good or bad?

Quick Heal Technologies Ltd's latest results are concerning, showing a 21.39% revenue decline and an operating loss of ₹17.57 crores, indicating severe operational challenges and a structural deterioration in financial performance. Investors may view these results negatively, as the company struggles in a competitive market.

Quick Heal Technologies Ltd's latest results are concerning and indicate a troubling trend for the company. In the first quarter of FY27, the company reported a significant year-on-year revenue decline of 21.39%, bringing total revenue down to ₹44.99 crores, which is the lowest quarterly sales figure in recent history. Additionally, the company faced an operating loss of ₹17.57 crores, resulting in a negative operating margin of 39.05%. This indicates that the company's operational challenges are severe.<BR><BR>The net loss for the quarter was ₹5.28 crores, which is a 4.17% increase in losses compared to the previous year. The financial performance reflects a structural deterioration rather than a temporary setback, as the company's cost structure is misaligned with its revenue generation capabilities. Employee costs consumed 96% of the revenue, highlighting the unsustainable nature of its current operations.<BR><BR>Overall, the results paint a picture of a company struggling to maintain its position in a competitive cybersecurity market, with significant challenges ahead. Investors are likely to view these results negatively, and the stock has been trading significantly below its 52-week high, reflecting skepticism about the company's future prospects.

When is the next results date for Quick Heal Technologies Ltd?

The next results date for Quick Heal Technologies Ltd is 21 May 2026.

The next results date for Quick Heal Technologies Ltd is scheduled for 21 May 2026.

Is Quick Heal Tech technically bullish or bearish?

As of December 2, 2025, Quick Heal Tech's technical stance is bearish with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mildly bullish indicators, and a significant year-to-date decline of 54.12% compared to the Sensex's 8.96%.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Quick Heal Tech is bearish with moderate strength. Key indicators driving this stance include the bearish signals from the daily moving averages and the weekly Bollinger Bands, alongside a bearish monthly MACD. Although the weekly MACD and KST show mildly bullish tendencies, the overall monthly indicators remain bearish, reinforcing the bearish outlook. The stock's recent performance, with a significant year-to-date decline of 54.12% compared to the Sensex's 8.96%, further supports this bearish sentiment.

How has been the historical performance of Quick Heal Tech?

Quick Heal Tech has experienced a significant decline in financial performance, with net sales dropping from INR 341.90 crore in March 2022 to INR 279.53 crore in March 2025, and operating profit turning negative at -INR 6.59 crore. Key metrics such as profit before tax and earnings per share have also sharply decreased during this period.

Answer:<BR>The historical performance of Quick Heal Tech shows a fluctuating trend in key financial metrics over the years, with significant declines in recent periods.<BR><BR>Breakdown:<BR>Quick Heal Tech's net sales have seen a decline from INR 341.90 crore in March 2022 to INR 279.53 crore in March 2025, with a slight recovery from INR 278.09 crore in March 2023. The total operating income followed a similar pattern, peaking at INR 341.90 crore in March 2022 and dropping to INR 279.53 crore by March 2025. The company's total expenditure, excluding depreciation, increased from INR 235.04 crore in March 2022 to INR 286.12 crore in March 2025, contributing to an operating profit (PBDIT) that turned negative at -INR 6.59 crore in March 2025, down from a high of INR 126.06 crore in March 2022. Profit before tax also fell sharply from INR 108.68 crore in March 2022 to INR 1.00 crore in March 2025, while profit after tax decreased from INR 83.19 crore to INR 5.04 crore in the same period. The earnings per share (EPS) reflected this downturn, dropping from INR 14.34 in March 2022 to INR 0.93 in March 2025. On the balance sheet, total assets decreased from INR 715.88 crore in March 2022 to INR 517.10 crore in March 2025, while total liabilities also decreased from INR 715.88 crore to INR 517.10 crore, indicating a consistent reduction in both assets and liabilities. The cash flow from operating activities turned negative at -INR 22.00 crore in March 2025, contrasting with positive cash flows in earlier years. Overall, Quick Heal Tech has experienced a significant decline in financial performance over the past few years.

Who are the top shareholders of the Quick Heal Tech?

The top shareholder of Quick Heal Tech is Sanjay Sahebrao Katkar, holding 28.86%. Other notable shareholders include 22 foreign institutional investors with 2.02%, a mutual fund with 1.13%, and individual investors collectively holding 19.14%.

The top shareholders of Quick Heal Tech include the promoters, with Sanjay Sahebrao Katkar holding the largest share at 28.86%. There are no pledged promoter holdings. Additionally, institutional investors include 22 foreign institutional investors (FIIs) who collectively hold 2.02%, and one mutual fund scheme that holds 1.13%. Among public shareholders, the highest holding is by Carnelian Structural Shift Fund at 1.22%. Individual investors collectively hold 19.14% of the company.

Is Quick Heal Tech overvalued or undervalued?

As of February 5, 2025, Quick Heal Technologies Ltd. is considered overvalued with a PE ratio of 393.95 and negative EV to EBITDA, indicating significant profitability concerns and unfavorable comparisons to peers, despite a recent stock price surge.

As of 5 February 2025, Quick Heal Technologies Ltd. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued, particularly highlighted by its PE ratio of 393.95 and an EV to EBITDA ratio of -272.02, which suggests severe profitability concerns. Additionally, the ROCE stands at -7.86%, further emphasizing the challenges the company faces in generating returns on capital.<BR><BR>In comparison to its peers, Quick Heal's valuation metrics are starkly unfavorable; for instance, its PE ratio is substantially higher than industry averages, while its EV to EBITDA is negative, indicating potential operational inefficiencies. Notably, the company’s PEG ratio is 0.00, which raises questions about future growth prospects. Despite a recent surge in stock price, with a 1-week return of 22.18% compared to the Sensex's 1.38%, the overall valuation suggests that Quick Heal Technologies Ltd. remains overvalued in the current market landscape.

Has Quick Heal Tech declared dividend?

Quick Heal Technologies Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of August 30, 2024. While recent returns have been negative, the company has shown significant growth over the longer term, particularly a total return of 243.34% over the past 5 years.

Quick Heal Technologies Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 30 Aug 24<BR><BR>Dividend Yield: 0.82%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -45.2%, with a dividend return of 0%, resulting in a total return of -45.2%.<BR><BR>Over the past year, the price return was -21.75%, the dividend return was 0.69%, leading to a total return of -21.06%.<BR><BR>In the 2-year period, the price return was 118.34%, the dividend return was 3.43%, culminating in a total return of 121.77%.<BR><BR>For the 3-year period, the price return was 105.86%, the dividend return was 6.71%, resulting in a total return of 112.57%.<BR><BR>In the last 4 years, the price return was 51.9%, with a dividend return of 5.15%, leading to a total return of 57.05%.<BR><BR>Over the past 5 years, the price return was 231.23%, the dividend return was 12.11%, resulting in a total return of 243.34%.<BR><BR>Overall, Quick Heal Technologies Ltd has declared a dividend, and while the recent returns over shorter periods have been negative, the longer-term returns show significant growth, particularly in the 5-year period.